Reckitt Benckiser (RB) has formed a 3-year collaboration with Bristol-Myers Squibb to market seven OTC brands in Brazil, Mexico and certain other parts of Latin America. The products, which generated unaudited net revenue of US$102 M in 2012, include Naldecon® (phenylephrine) for coughs and colds, the effervescent antacid Picot® (sodium bicarbonate) and Tempra® (acetaminophen) for pain relief. RB has an option to purchase the brands at the end of the collaboration term, subject to business performance. The deal is the latest move by RB to strengthen its consumer healthcare business.